IN2012DN01572A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01572A IN2012DN01572A IN1572DEN2012A IN2012DN01572A IN 2012DN01572 A IN2012DN01572 A IN 2012DN01572A IN 1572DEN2012 A IN1572DEN2012 A IN 1572DEN2012A IN 2012DN01572 A IN2012DN01572 A IN 2012DN01572A
- Authority
- IN
- India
- Prior art keywords
- methods
- subject
- same
- compositions
- improved pharmacokinetic
- Prior art date
Links
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 abstract 4
- 229960001570 ademetionine Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 235000003715 nutritional status Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918609P | 2009-07-28 | 2009-07-28 | |
| PCT/IB2010/001879 WO2011012990A2 (en) | 2009-07-28 | 2010-07-29 | Improved pharmacokinetics of s-adenosylmethionine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01572A true IN2012DN01572A (enExample) | 2015-06-05 |
Family
ID=43527262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1572DEN2012 IN2012DN01572A (enExample) | 2009-07-28 | 2010-07-29 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US8329208B2 (enExample) |
| EP (1) | EP2464358B1 (enExample) |
| JP (1) | JP2013505897A (enExample) |
| KR (1) | KR20120068001A (enExample) |
| CN (1) | CN102724971A (enExample) |
| AU (1) | AU2010277302B2 (enExample) |
| CA (1) | CA2769490C (enExample) |
| IN (1) | IN2012DN01572A (enExample) |
| WO (1) | WO2011012990A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| US20130064889A1 (en) * | 2011-09-13 | 2013-03-14 | Aptapharma, Inc. | Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof |
| CA2888302C (en) | 2012-10-17 | 2016-05-31 | Methylation Sciences International Srl | Compositions comprising s-adenosylmethionine and a gallic acid ester |
| JP6237760B2 (ja) * | 2013-02-22 | 2017-11-29 | ゼリア新薬工業株式会社 | 腸溶錠 |
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| SI2968529T1 (sl) * | 2013-03-14 | 2021-03-31 | Aimmune Therapeutics, Inc. | Izdelava arašidovih formulacij arašida za ustno desenzibilizacijo |
| CN105101974B (zh) * | 2013-04-05 | 2018-07-03 | 狮王株式会社 | 内服组合物 |
| US9409139B2 (en) | 2013-08-05 | 2016-08-09 | Twist Bioscience Corporation | De novo synthesized gene libraries |
| ITMI20131906A1 (it) | 2013-11-18 | 2015-05-19 | Gnosis Spa | Composizioni solide orali a lento rilascio |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| AU2016324296A1 (en) | 2015-09-18 | 2018-04-12 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| CA3034769A1 (en) | 2016-08-22 | 2018-03-01 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
| CN110248724B (zh) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| CN110366613A (zh) | 2016-12-16 | 2019-10-22 | 特韦斯特生物科学公司 | 免疫突触的变体文库及其合成 |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| CN110913865A (zh) | 2017-03-15 | 2020-03-24 | 特韦斯特生物科学公司 | 免疫突触的变体文库及其合成 |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| KR102637566B1 (ko) | 2017-10-20 | 2024-02-16 | 트위스트 바이오사이언스 코포레이션 | 폴리뉴클레오타이드 합성을 위한 가열된 나노웰 |
| CN112041438B (zh) | 2018-01-04 | 2025-05-23 | 特韦斯特生物科学公司 | 基于dna的数字信息存储 |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| EP3836801A4 (en) | 2018-08-16 | 2022-05-18 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy with maintenance dose |
| CN113891722A (zh) | 2018-12-20 | 2022-01-04 | 爱沐疗法公司 | 用于漏服剂量的花生口服免疫疗法给药计划表 |
| CA3124980A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| KR102217379B1 (ko) | 2019-01-28 | 2021-02-17 | 이청용 | 다층구조의 태양광 led 조명등과 끈끈이 해충유인 솔라백이 구비된 해충 포획 및 야생동물 퇴치 트랩 |
| CN113785057A (zh) | 2019-02-26 | 2021-12-10 | 特韦斯特生物科学公司 | 用于抗体优化的变异核酸文库 |
| KR20210143766A (ko) | 2019-02-26 | 2021-11-29 | 트위스트 바이오사이언스 코포레이션 | Glp1 수용체에 대한 변이체 핵산 라이브러리 |
| EP3965815A4 (en) | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| JP2022550497A (ja) | 2019-06-21 | 2022-12-02 | ツイスト バイオサイエンス コーポレーション | バーコードに基づいた核酸配列アセンブリ |
| JP2021046375A (ja) * | 2019-09-19 | 2021-03-25 | ポッカサッポロフード＆ビバレッジ株式会社 | β３アドレナリン受容体活性化剤 |
| AU2020355027A1 (en) | 2019-09-23 | 2022-04-21 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CA3155629A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| KR20210112965A (ko) | 2020-03-07 | 2021-09-15 | 이청용 | 우수가림막과 다층구조의 태양광 엘이디조명등이 구비된 끈끈이 해충 포획 및 야생동물 퇴치 트랩 |
| AU2024274445A1 (en) | 2023-05-15 | 2025-11-27 | Bonafide Health, Llc | Sleep-improving compositions and methods of use |
| KR102763656B1 (ko) | 2024-06-10 | 2025-02-07 | 경상북도(농업기술원) | 해충 개체정보 모니터링용 포충 트랩장치 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE37913B1 (en) | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
| IE39517B1 (en) | 1973-06-27 | 1978-10-25 | Bioresearch Sas | Double salts of s-adenosyl-l-methhionine |
| AR221676A1 (es) | 1974-07-12 | 1981-03-13 | Bioresearch Sas | Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico |
| US5264446A (en) | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
| US4525345A (en) | 1981-12-24 | 1985-06-25 | Verex Laboratories, Inc. | Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4556678A (en) | 1982-06-24 | 1985-12-03 | Key Pharmaceuticals, Inc. | Sustained release propranolol tablet |
| DE3435325A1 (de) | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung |
| IT1169772B (it) | 1983-08-24 | 1987-06-03 | Bioresearch Spa | Composizioni terapeutiche per uso orale contenenti sali stabili della s-adenosil-l-metionina |
| US4680323A (en) | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
| US4537772A (en) | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
| IT1173992B (it) | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale |
| US4601894A (en) | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| US4695591A (en) | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
| US4687757A (en) | 1986-03-24 | 1987-08-18 | Phillips Petroleum Company | Hydrofining catalyst composition and process for its preparation |
| US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
| US5073380A (en) | 1987-07-27 | 1991-12-17 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| FR2623396B1 (fr) | 1987-11-25 | 1990-03-30 | Sanofi Sa | Utilisation de l'ademetionine contre le vieillissement de la peau |
| US5169642A (en) | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
| IT1229477B (it) | 1989-03-13 | 1991-09-03 | Bioresearch Spa | Impiego di 5' deossi - 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative |
| US5137712A (en) | 1990-08-31 | 1992-08-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment |
| IT1243859B (it) | 1990-10-23 | 1994-06-28 | Bioresearch Spa | Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids. |
| US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| IL104192A (en) | 1992-02-17 | 1998-01-04 | Siegfried Ag Pharma | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient |
| AU721067B2 (en) | 1995-04-25 | 2000-06-22 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| DE19631084A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
| DE19631085A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut |
| US5922341A (en) | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
| WO1999043336A1 (en) | 1998-02-27 | 1999-09-02 | Nutramax Laboratories, Inc. | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| DE19839443A1 (de) | 1998-08-29 | 2000-03-02 | Miklos Ghyczy | Arnzneimittel mit entzündungshemmender Wirkung |
| EP1027885B1 (en) | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6685928B2 (en) | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
| CA2405360A1 (en) | 2000-04-07 | 2001-10-18 | The Board Of Regents Of The University Of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| AU2002228321A1 (en) | 2000-12-18 | 2002-07-01 | Orchid Chemicals And Pharmaceuticals Limited | A novel soft-gelatin capsule comprising s-adenosylmethionine and a method for producing the same |
| US6759395B2 (en) | 2000-12-18 | 2004-07-06 | Orchid Chemicals & Pharmaceuticals, Ltd. | Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same |
| GB0109428D0 (en) | 2001-04-17 | 2001-06-06 | Process & Ind Design Consultan | Therapeutic compositions |
| GB0111579D0 (en) | 2001-05-11 | 2001-07-04 | Holford & Associates Ltd | Oral supplement |
| JP3908513B2 (ja) | 2001-11-19 | 2007-04-25 | 日本甜菜製糖株式会社 | 肝機能改善剤 |
| WO2004000280A1 (en) | 2002-04-29 | 2003-12-31 | Shire Laboraties, Inc. | Pharmaceutical formulations with improved bioavailability |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050158382A1 (en) | 2003-09-26 | 2005-07-21 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
| JP5069001B2 (ja) * | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | フィブラートを含む固体投与形態 |
| WO2005041926A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| EP1701705A4 (en) | 2003-12-24 | 2007-08-08 | Advancis Pharmaceutical Corp | IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE |
| WO2005065661A2 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
| US7429569B2 (en) | 2004-01-29 | 2008-09-30 | Fast Balance, Inc. | Compositions and methods for the regulation of homocysteine levels within the body |
| US20050181047A1 (en) | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements |
| WO2006044202A2 (en) | 2004-10-19 | 2006-04-27 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
| US20060127506A1 (en) | 2004-12-10 | 2006-06-15 | Hebert Rolland F | Compositions of S-adenosyl-L-methionine |
| US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US8063024B2 (en) | 2005-01-26 | 2011-11-22 | University Of Manitoba | Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance |
| DE102005024614A1 (de) | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| DK1731596T5 (da) | 2005-06-09 | 2013-09-23 | Gnosis Spa | Tørrede, frysetørrede og/eller mikroindkapslede celler af Saccharomyces cerevisiae med et højt indhold af (S)-(+)-S-adenosyl-L-methionin |
| EP1896002A4 (en) | 2005-06-27 | 2009-11-25 | Biovail Lab Int Srl | BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE |
| AR059423A1 (es) | 2006-02-09 | 2008-04-09 | Univ Maryland | Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables |
| BRPI0707616A2 (pt) | 2006-02-09 | 2011-05-10 | Alba Therapuetics Corp | formulaÇÕes para um efetor de junÇço oclusiva |
| ITMI20060629A1 (it) | 2006-03-31 | 2007-10-01 | Daniele Giovannone | Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento |
| US20100062073A1 (en) * | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| US20090197824A1 (en) | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20090088404A1 (en) | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20080206333A1 (en) | 2007-01-31 | 2008-08-28 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20080279931A1 (en) | 2007-05-09 | 2008-11-13 | Northern Holdings Inc. | Composition for treatment of pain |
| ITMI20081405A1 (it) | 2008-07-29 | 2010-01-30 | Velleja Res Srl | Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia |
| WO2010027014A1 (ja) | 2008-09-04 | 2010-03-11 | 株式会社カネカ | Ｓ－アデノシル－ｌ－メチオニンの吸収性を高める方法およびｓ－アデノシル－ｌ－メチオニンの吸収性が高められた組成物 |
| EP2193787A1 (en) | 2008-12-02 | 2010-06-09 | Giorgio Stramentinoli | Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| US20110027342A1 (en) | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
-
2010
- 2010-07-28 US US12/845,600 patent/US8329208B2/en active Active
- 2010-07-29 CN CN2010800447195A patent/CN102724971A/zh active Pending
- 2010-07-29 IN IN1572DEN2012 patent/IN2012DN01572A/en unknown
- 2010-07-29 AU AU2010277302A patent/AU2010277302B2/en not_active Ceased
- 2010-07-29 WO PCT/IB2010/001879 patent/WO2011012990A2/en not_active Ceased
- 2010-07-29 EP EP10751713.8A patent/EP2464358B1/en not_active Ceased
- 2010-07-29 JP JP2012522273A patent/JP2013505897A/ja active Pending
- 2010-07-29 KR KR1020127005234A patent/KR20120068001A/ko not_active Ceased
- 2010-07-29 CA CA2769490A patent/CA2769490C/en not_active Expired - Fee Related
-
2012
- 2012-12-05 US US13/706,188 patent/US8865203B2/en active Active
- 2012-12-13 US US13/714,246 patent/US8580296B2/en active Active
-
2014
- 2014-08-28 US US14/472,204 patent/US20140370108A1/en not_active Abandoned
-
2016
- 2016-08-23 US US15/245,105 patent/US9931356B2/en active Active
-
2018
- 2018-02-22 US US15/902,877 patent/US20190060345A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130149350A1 (en) | 2013-06-13 |
| US8329208B2 (en) | 2012-12-11 |
| KR20120068001A (ko) | 2012-06-26 |
| CA2769490A1 (en) | 2011-02-03 |
| US20110027360A1 (en) | 2011-02-03 |
| US20160361339A1 (en) | 2016-12-15 |
| JP2013505897A (ja) | 2013-02-21 |
| US8580296B2 (en) | 2013-11-12 |
| CA2769490C (en) | 2014-04-01 |
| US9931356B2 (en) | 2018-04-03 |
| AU2010277302A1 (en) | 2012-03-15 |
| WO2011012990A2 (en) | 2011-02-03 |
| EP2464358A2 (en) | 2012-06-20 |
| US20140370108A1 (en) | 2014-12-18 |
| CN102724971A (zh) | 2012-10-10 |
| EP2464358B1 (en) | 2015-06-17 |
| US20130129792A1 (en) | 2013-05-23 |
| AU2010277302B2 (en) | 2014-06-05 |
| WO2011012990A3 (en) | 2011-06-16 |
| US8865203B2 (en) | 2014-10-21 |
| US20190060345A1 (en) | 2019-02-28 |
| WO2011012990A8 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01572A (enExample) | ||
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| WO2013072932A3 (en) | Oral care compositions | |
| IN2014DN09434A (enExample) | ||
| MX344925B (es) | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. | |
| MY173008A (en) | Methods and compositions for improving gut microbiota population | |
| TN2014000110A1 (en) | Dual function proteins for treating metabolic disorders | |
| SG178991A1 (en) | Anti-gitr antibodies | |
| WO2009155513A3 (en) | Immunoglobulins with reduced aggregation | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| SG10201406300YA (en) | L-ornithine phenyl acetate and methods of making thereof | |
| MY152437A (en) | Oral care compositions | |
| MX352992B (es) | Prevencion y tratamiento de la enfermedad de nosema en abejas. | |
| WO2013006336A3 (en) | Methods and compositions useful for treating fitzpatrick type iv, v or vi skin | |
| HK1216717A1 (zh) | 用於治療葡萄糖轉運體1缺乏症的三庚酸甘油酯 | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| HK1206646A1 (en) | Dosage forms of halofuginone and methods of use | |
| WO2011075606A3 (en) | Hyperglycosylated polypeptide variants and methods of use | |
| BR112016028973A2 (pt) | composições antagonistas de receptor de sabor doce | |
| BR112015008490A2 (pt) | composições e métodos para fermentados rico em vitamina | |
| BR112012007418A2 (pt) | Composições nutricionais incluindo teanina e nucleotídeos exógenos. | |
| MX2011011559A (es) | Parasiticidas sanguineos. | |
| MX350259B (es) | Apoaequorina para reducir daño neuronal debido a isquemia. | |
| EA201590471A1 (ru) | Глазированные пищевые продукты с шоколадной сердцевиной и способ их получения | |
| EP2533796A4 (en) | METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES |